Advertisement
Screener

Altamira Therapeutics Ltd. (CYTOF) Increase Decrease In Cash And Cash Equivalents

2.8 / 5 stars · 68/120 Roast Me

Altamira Therapeutics Ltd. Increase Decrease In Cash And Cash Equivalents

Altamira Therapeutics Ltd. (CYTOF) reported Increase Decrease In Cash And Cash Equivalents of -$1.02 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-29.

Financial Statements › Notes

ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2025-08-29

CHF

Period endIncrease Decrease In Cash And Cash Equivalents 6 monthIncrease Decrease In Cash And Cash Equivalents 12 month
2023-12-31555.42K CHF
20-F/A · filed 2024-04-22
2023-06-30-16.23K CHF
6-K · filed 2023-09-12
2022-12-31-993.07K CHF
20-F/A · filed 2024-04-22
2022-06-30-575.39K CHF
6-K · filed 2023-09-12
2021-12-31-10.56M CHF
20-F/A · filed 2024-04-22
2021-06-30-3.06M CHF
6-K/A · filed 2023-08-21
2020-12-319.80M CHF
20-F · filed 2023-05-16
2020-06-30-1.35M CHF
6-K · filed 2021-09-08
2019-12-31-4.02M CHF
20-F · filed 2022-04-12
2019-06-30362.91K CHF
6-K/A · filed 2020-09-17
2018-12-31-9.32M CHF
20-F · filed 2021-03-31
2018-06-30-10.40M CHF
6-K · filed 2019-08-15
2017-12-31-16.15M CHF
20-F · filed 2020-04-16

USD

Period endIncrease Decrease In Cash And Cash Equivalents 6 monthIncrease Decrease In Cash And Cash Equivalents 12 month
2025-06-30-$1.02M
6-K · filed 2025-08-29
2024-12-31$276.28K
20-F · filed 2025-04-30
2024-06-30-$688.44K
6-K · filed 2025-08-29
2023-12-31$618.16K
20-F · filed 2025-04-30
2023-06-30-$17.79K
6-K · filed 2024-09-24
2022-12-31-$1.04M
20-F · filed 2025-04-30